{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:10Z","timestamp":1793744650357,"version":"4.6.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neoadjuvant immunotherapy is reshaping the treatment of resectable solid tumors, but biomarkers that reflect spatially organized antitumor immunity remain limited. Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that support local antigen presentation, lymphocyte recruitment, T\u2013B cell interaction, germinal center reactions and humoral immunity. Increasing evidence suggests that TLS density, maturation, localization and cellular composition are associated with immune checkpoint blockade response, pathological regression and prognosis. Beyond their biomarker value, TLS may represent modifiable immune niches that can be induced or remodeled by checkpoint blockade, chemotherapy, radiotherapy, vaccines and stromal\u2013vascular strategies. This mini-review discusses the biological basis, biomarker potential, therapeutic targeting and clinical translation of TLS in neoadjuvant cancer immunotherapy, highlighting key challenges and future TLS-guided trial designs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1882195","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:19:46Z","timestamp":1782904786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Tong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Reproduction, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Reproduction, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Reproduction, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1771228","article-title":"Clinicopathological and molecular characteristics associated with pathological complete response in neoadjuvant immunotherapy for breast cancer","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369626","article-title":"Tertiary lymphoid structures in cancer: maturation\u00a0and induction","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115572","article-title":"Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy","volume":"225","author":"Vion","year":"2025","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1480461","article-title":"Mature tertiary lymphoid\u00a0structure associated CD103+ CD8+ Trm cells determined improved anti-tumor immune in breast cancer","volume":"15","author":"Fang","year":"2025","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","article-title":"Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15175","article-title":"Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study","volume":"15","author":"Xu","year":"2024","journal-title":"Thorac Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.medj.2024.10.023","article-title":"Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside","volume":"6","author":"Peyraud","year":"2025","journal-title":"Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.13","article-title":"Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy","volume":"14","author":"Tang","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01678-9","article-title":"Decoding the tumor microenvironment with spatial technologies","volume":"24","author":"Walsh","year":"2023","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148129","article-title":"Fibulin 1, targeted by microRNA-24-3p, promotes cell proliferation and migration in vascular smooth muscle cells, contributing to the development of atherosclerosis in APOE(-\/-) mice","volume":"898","author":"Ji","year":"2024","journal-title":"Gene"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101448","article-title":"An immune cell map of human\u00a0lung\u00a0adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: An intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1611oc","article-title":"Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2024.07.020","article-title":"Tertiary lymphoid structure in tumor microenvironment and immunotherapy of lung cancer","author":"Xie","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21417\/tc2020nm","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1348156","article-title":"Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures","volume":"15","author":"Omotesho","year":"2024","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03262-w","article-title":"The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-17-1987","article-title":"Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma","volume":"78","author":"Sili\u0146a","year":"2018","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1465516","article-title":"Tertiary lymphoid structures in ovarian cancer","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13143-w","article-title":"Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: A systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674375","article-title":"Therapeutic induction of tertiary lymphoid structures in cancer through stromal remodeling","volume":"12","author":"Johansson-Percival","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-3325","article-title":"Exploiting tertiary lymphoid structures to stimulate antitumor immunity and improve immunotherapy efficacy","volume":"84","author":"Petroni","year":"2024","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-025-03318-6","article-title":"Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade","volume":"44","author":"Li","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105003","article-title":"Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer","volume":"101","author":"Di Modugno","year":"2024","journal-title":"EBioMedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.095","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11864-021-00885-6","article-title":"Neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer","volume":"22","author":"Gutierrez-Sainz","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2024.27","article-title":"Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity","volume":"26","author":"Li","year":"2024","journal-title":"Expert Rev Mol Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2974","article-title":"Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma","volume":"27","author":"Zheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101796","article-title":"Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients","volume":"69","author":"Houel","year":"2023","journal-title":"Semin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2406576","article-title":"Immune priming and induction of tertiary lymphoid structures in a cord-blood humanized mouse model of gastrointestinal stromal tumor","volume":"13","author":"He","year":"2024","journal-title":"Oncoimmunology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02259-8","article-title":"Simultaneous STING and lymphotoxin-\u03b2 receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity","volume":"26","author":"Sawada","year":"2025","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005531","article-title":"Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-sitc2020.0602","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00551-9","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/path.5080","article-title":"Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules","volume":"245","author":"He","year":"2018","journal-title":"J Pathol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12957-023-03212-5","article-title":"Neoadjuvant PD-1\/PD-L1 combined with CTLA-4 inhibitors for solid Malignancies: a systematic review and meta-analysis","volume":"21","author":"Huang","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1882195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:19:47Z","timestamp":1782904787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1882195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2026.1882195"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1882195","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1882195"}}